The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 87-90 , January 2003

Omalizumab, a recombinant humanized anti-IgE antibody, reduces asthma-related emergency room visits and hospitalizations in patients with allergic asthma

Received 1 January 2002 ,Revised 1 January 2002 ,Accepted 1 January 2002.

References 

  1. Global Initiative for Asthma GINA . Global strategy for asthma management and prevention. NHBLI/WHO workshop report NIH publication number 95-3659 National Institutes of Health, National Heart, Lung, and Blood Institute; January 1995;
  2. Weiss KB, Gergen PJ, Hodgson TA. An economic evaluation of asthma in the United States. N Engl J Med. 1992;326:862–866
  3. Smith DH, Malone DC, Lawson KA, Okamoto LJ, Battista C, Saunders WB. A national estimate of the economic costs of asthma. Am J Respir Crit Care Med. 1997;156:787–793
  4. Lemanske RF, Busse WW. Asthma. JAMA. 1997;278:1855–1873
  5. Fick RB. Anti-IgE as novel therapy for the treatment of asthma. Curr Opin Pulmon Med. 1999;5:76–80
  6. Easthope S, Jarvis B. Omalizumab. Drugs. 2001;61:253–260
  7. Busse W, Corren J, Lanier BQ, McAlary M, Fowler-Taylor A, Cioppa GD, et al.  Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol. 2001;108:184–190
  8. Milgrom H, Berger W, Nayak A, Gupta N, Pollard S, McAlary M, et al.  Treatment of childhood asthma with anti-IgE antibody (omalizumab). Pediatrics. 2001;108:e36
  9. Solèr M, Matz J, Townley R, Buhl R, O'Brien J, Fox H, et al  The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J. 2001;18:254–261
  10. Efron B, Tibshirani RJ. An Introduction to the bootstrap. New York: Chapman & Hall; 1993;
  11. Buhl R, Solèr M, Matz J, Townley R, O'Brien J, Noga O, et al.  Omalizumab provides long-term control in patients with moderate-to-severe allergic asthma. Eur Respir J. 2002 Jul;20:73–78
  12. Crane J, Pearce N, Burgess C, Woodman K, Robson B, Beasley R. Markers of risk of asthma death or readmission in the 12 months following a hospital admission for asthma. Int J Epidemiol. 1992;21:737–744
  13. Nicholson KG, Kent J, Ireland DC. Respiratory viruses and exacerbations of asthma in adults. BMJ. 1993;307:982–986
  14. Johnston SL, Pattemore PK, Sanderson G, Smith S, Lampe F, Josephs L, et al.  Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ. 1995;310:1225–1229
  15. Green RM, Custovic A, Sanderson G, Hunter J, Johnston SL, Woodcock A. Synergism between allergens and viruses and risk of hospital admission with asthma: case-control study. BMJ. 2002;324:1–5

☆ Supported in part by Novartis Pharma AG, Basel, Switzerland, and Genentech, Inc, South San Francisco, Calif.

☆☆ Reprint requests: Jonathan Corren, MD, Allergy Research Foundation, Inc, 1160 Wilshire Blvd, Suite 200, Los Angeles, CA 90025.

PII: S0091-6749(02)91311-4

doi: 10.1067/mai.2003.49

The Journal of Allergy and Clinical Immunology
Volume 111, Issue 1 , Pages 87-90 , January 2003

Article Tools

* Image Usage & Resolution